BIOA

The Prime Minister was also briefed about the recently launched BioA!-Safety and National Lab Policies which received very positive feedback.

(NYSE and EURONEXT Paris: BIOA), has received a CAD10m interest free loan from Agriculture Canada.

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B), a Swedish research-based biopharma company, announced yesterday that it has started the first clinical study with ABBV-0805 in the United States.

BioAmber Inc (NYSE and EURONEXT Paris: BIOA), an industrial biotechnology company producing renewable chemicals, has reported its financial results for the three months ended September 30, 2013.

BioAmber Inc (NYSE and EURONEXT Paris: BIOA), a sustainable chemicals company, has signed a European distribution agreement with IMCD Group, a market-leader in the sales, marketing and distribution of speciality chemicals and food ingredients.

- Swedish biopharmaceutical company BioArctic AB (NASDAQ Stockholm: BIOA B) has signed an expanded research collaboration agreement with Uppsala University, in Sweden, Department of Public Health and Caring Sciences, Molecular Geriatrics, the company said.

BioArctic AB (Stockholm: BIOA), a Swedish research-based biopharmaceutical company, announced on Tuesday that results of the BAN2401 phase 2b clinical study (ClinicalTrials.gov identifier NCT01767311) have been accepted for presentation at the 2018 Alzheimer's Association International Conference (AAIC).

BioArctic AB (Stockholm: BIOA), a Swedish research-based biopharmaceutical company, announced on Tuesday the receipt of approval by Fimea, the Finnish Medicines Agency, and Valvira, the Finnish authority for medical device, as well as the local ethics committee, for inclusion of Finnish patients in BioArctic's ongoing clinical phase 1/2 study with SC0806.

- Stockholm, Sweden-based research biopharmaceutical company BioArctic AB (STO: BIOA B) has presented positive topline results from the clinical Phase 2b study of BAN2401 in 856 patients with early Alzheimer's disease at the Alzheimer's Association International Conference (AAIC 2018), the company said.

- Stockholm, Sweden-based research biopharmaceutical company BioArctic AB (STO: BIOA B) has released positive topline results from the phase 2b study with BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's dementia with confirmed amyloid pathology in the brain at the start of the study, the company said.

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B), a Swedish research-based biopharma company, has revealed positive top-line results from the Phase 2b study with BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer's disease, it is reported today.

- Stockholm, Sweden-based research based biopharma company BioArctic AB (NASDAQ Stockholm: BIOA B) has signed an extended research collaboration agreement with Uppsala University, Department of Pharmaceutical Biosciences, the company said.